Who Supplies Amiodarone to India from AUSTRALIA

To import finished pharmaceutical formulations containing Amiodarone into India, the Central Drugs Standard Control Organization (CDSCO) mandates that the importer obtain an Import Registration Certificate and an Import License as per the Drugs and Cosmetics Act and Rules. The registration process involves submitting Form 40 or 41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration can vary, but it typically takes several months to complete. For formulations under HS Code 30049099, the importer must ensure compliance with all regulatory requirements, including obtaining a No Objection Certificate (NOC) from CDSCO, if applicable.

Imported finished pharmaceutical formulations containing Amiodarone are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) and stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV standards. The formulations must meet the standards specified in the Indian Pharmacopoeia. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity and quality of the imported products. Any discrepancies or failures in quality testing can lead to delays, rejections, or destruction of the goods.

In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing Amiodarone. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. Bilateral agreements between India and Australia have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), thereby streamlining the import process for Australian pharmaceutical products.

India imports finished Amiodarone formulations to meet the demand for patented or branded products, specific dosage forms, and formulations not available domestically. The domestic capacity for manufacturing Amiodarone formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Amiodarone formulations in India is substantial, with a significant volume of imports to cater to the therapeutic requirements of patients.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. The Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which can vary. There are no specific exemptions or concessional duty rates for Australian-origin products under this HS code. The total landed duty percentage combines these components, affecting the final cost of imported goods.

India sources finished Amiodarone formulations from Australia due to the availability of patented formulations, specialized dosage forms, and high-quality products. Australian manufacturers adhere to stringent quality standards, ensuring the safety and efficacy of their products. While other suppliers like China, Germany, and the United States also export Amiodarone formulations to India, Australia's share remains significant due to its competitive advantages in quality and regulatory compliance.

India imports finished Amiodarone formulations from Australia due to the availability of patented formulations, specialized dosage forms, and high-quality products. Australian manufacturers adhere to stringent quality standards, ensuring the safety and efficacy of their products. These formulations are often not available domestically, making imports essential to meet the therapeutic needs of patients.

When compared to other origins like China, the European Union, and the United States, Australia offers competitive advantages in terms of product quality, regulatory compliance, and reliability. Australian pharmaceutical products are known for their adherence to international standards, which is crucial for the Indian market. While other countries may offer lower prices, Australia's consistent quality and compliance with regulatory requirements make it a preferred source for importing Amiodarone formulations.

Indian importers face several supply chain risks when sourcing finished Amiodarone formulations from Australia, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure flexibility in procurement.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 to CDSCO for product registration.
3. 3Import License: Apply for an Import License as per the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): Obtain an NOC from CDSCO, if required.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: